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ABSTRACT
Background: Implementation of the newly approved high-sensitivity cardiac 
troponin (hs-cTn) in the United States presents a challenge for clinical 
practice. Sex-specific cut-offs, clinical protocols, and workflows will likely 
require modifications before implementation. 
Methods: We conducted a cross-sectional survey of international physicians 
and laboratorians already utilizing hs-cTn for the evaluation of acute 
myocardial infarction (AMI). 
Results: Twenty-two of 54 (41%) eligible participants completed the survey, 
representing nine countries and 18 hospitals. All reported successful hs-cTn 
implementation and diagnostic utility (mean 8.6+1.2 out of 10 for best 
implementation). The major perceived benefit was more rapid evaluation of 
AMI (14/19, 74%) and the most frequently cited limitation was an increase in 
the number of measurable hs-cTn values that required interpretation (8/18, 
44%). Institutions using the hs-cTnI assay favored sex-specific cut-offs (5/6, 
83%) while institutions using the hs-cTnT assay favored a combined cut-off 
(12/12, 100%). Timing of serial hs-cTn measurements varied, with 0-3 hours 
(8/17, 47%) most frequent, followed by 0-2 hours (4/17, 24%), 0-1 hour 
(3/17, 18%), and other (2/17, 12%). 
Conclusions: Our survey of hs-cTn implementation at international 
institutions reveals satisfaction with new assays but reflects important 
variations in clinical practice. The use of sex-specific vs combined cut-offs 
and timing of serial hs-cTn measurements varies across institutions and are 
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subjects that US centers must define without consensus from international 
practices. 
Keywords: High-sensitivity cardiac troponin, acute myocardial infarction, 
clinical implementation 
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INTRODUCTION
High-sensitivity cardiac troponin (hs-cTn) has been a key tool for 
diagnosis and exclusion of acute myocardial infarction (AMI) for nearly a 
decade outside the United States (US).1 In contrast, the US has used less 
sensitive “contemporary” cTn assays. On January 19, 2017, the US Federal 
Drug Administration (FDA) approved the first hs-cTn assay.
The strengths of hs-cTn assays are precise measurement of lower 
levels of troponin than contemporary assays and earlier identification of 
myocardial injury2,3—affording rapid rule-out and rule-in of AMI by 
accelerated diagnostic protocols.4-6 As defined by the International 
Federation for Clinical Chemistry (IFCC), a “high sensitivity” cTn assay 
exhibits ≤10% coefficient of variation, or imprecision, at the cut-off for the 
reference population and has the capacity to measure troponins less than 
the cut-off in at least 50% of healthy individuals.7 In contrast, contemporary 
assays exhibit analytical imprecision >10% at the cut-off, and at best, can 
quantify troponins in up to 35% of healthy individuals.7 For hs-cTn assays, 
sex-specific cut-offs have also been proposed by the IFCC due to reported 
differences at each respective cut-off according to sex,8 although data are 
conflicting on whether or not sex-specific cut-offs result in improved clinical 
outcomes.9,10 Two hs-cTn assays, hs-cTnT (Roche Diagnostics, Rotkreuz, 
Switzerland) and hs-cTnI (Abbott Diagnostics, Chicago, IL), have been widely 
employed clinically outside the US. 
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Despite perceived benefits, the clinical implementation of hs-cTn 
presents several challenges. Sex-specific cut-offs,11,12 various clinical 
protocols and workflows,13,14 and different approaches to educate providers 
may become significant barriers to hs-cTn adoption. Strategies for defining 
and/or overcoming potential challenges are not well described. We sought to 
characterize practices associated with successful hs-cTn implementation 
outside the US by surveying physicians and laboratorians from institutions 
that have implemented hs-cTn for the evaluation of AMI.
METHODS
We conducted a cross-sectional survey of physicians and laboratorians 
at institutions outside the US using hs-cTn for standard patient care. We 
included (1) authors of PubMed-indexed studies involving hs-cTn for the 
evaluation of AMI and (2) physicians and laboratory scientists identified by 
these authors as having a critical role in the implementation of hs-cTn at 
their institution. We excluded physicians and laboratorians who are from the 
US, those who were associated with institutions that did not clinically use hs-
cTn, or were not involved with the implementation of hs-cTn. The survey was
hosted by Qualtrics (Qualtrics, Provo, UT) online survey platform. We 
distributed email invitations with a web link to the online survey to eligible 
participants from July to August 2017. We made up to four attempts over two
months to recruit eligible participants.
The survey assessed the clinical implementation process of hs-cTn 
including the major topics of: (1) clinical use of hs-cTn, (2) effects of 
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implementation, (3) challenges in implementation, and (4) leadership and 
education (Appendix). Survey questions were developed based on expert 
opinion and literature review. The survey was pilot tested on three subjects. 
Minor revisions were made based on the pilot testing and pilot responses 
were included in the final analysis.
Our primary outcome was participants' overall rating of the success of 
hs-cTn clinical implementation, ranging from 0 for "not at all successful" to 
10 for "extremely successful." For open-ended questions, we identified 
themes in the responses which were coded and analyzed quantitatively. 
We calculated proportions for each outcome. Continuous variables 
were expressed as mean ± standard deviation (SD) and analyzed by 
Student’s 2-sample t-test; categorical variables were analyzed by Chi square.
Differences were considered significant if p <0.05. The JMP statistical 
package (JMP 13.0.0, SAS Institute Inc., Cary, NC) was used for analysis. This 
study was deemed not to be human subjects research and was exempt from 
review by our institutional review board.
RESULTS
Of the 62 potential participants screened for eligibility, eight were 
excluded: six for not using hs-cTn clinically and two for not being involved in 
hs-cTn implementation. Of the 54 participants who met inclusion criteria, 22 
(41%, 22/54) completed the survey (Table 1). The participants represent 
nine countries, 18 institutions, and five departments (Table 1). Participants 
either use hs-cTnT (59%, 13/22) or hs-cTnI (41%, 9/22) assays. All 
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participants reported successful hs-cTn implementation and diagnostic utility
(8.6 ±1.2 out of 10 for best implementation). 
Clinical Use of hs-cTn. Institutions employing the hs-cTnI assay 
favored sex-specific cut-offs (5/6, 83%) while institutions using the hs-cTnT 
assay favored a combined cut-off (12/12, 100%) (Table 1). 
Timing of serial hs-cTn measurements varied, with 0 to 3 hours (8/17, 
47%) being the most frequent, followed by 0 to 2 hours (4/17, 24%), 0 to 1 
hour (3/17, 18%), and other (2/17, 12%) (Table 1). The two institutions that 
use an “other” timing interval included “physician-dependent, but many 
using 2-hour intervals” and “3 [hour] only if first [hs-cTn] is >5 ng/l.”
Nearly all institutions (16/18, 89%) integrate hs-cTn in a protocol for 
exclusion of AMI. The most frequent criteria used are ≥2 normal hs-cTn 
values (10/15, 67%) with approximately half also including a clinical risk 
score (8/15, 53%) and a normal electrocardiogram (7/15, 47%). 
In the protocols for exclusion of AMI in the emergency department, the 
majority (53%, 8/15) use additional cardiac testing at the discretion of the 
attending physician; 27% (4/15) require no additional cardiac testing, and 
20% (3/15) use additional cardiac functional testing as directed by protocol 
(Table 1). 
Effects of hs-cTn Implementation. Approximately three-fourths of 
participants (74%) identified more rapid rule-in and rule-out of AMI as a 
positive impact of hs-cTn implementation with comments such as: "Rapid 
rule out… Reduction in [length of stay] for low risk patients (12 hours to 6 
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hours)” and "… we implemented the 0/1 hour rule out protocol. 
Consequently, patients could be faster discharged or admitted... the duration
of patients in the emergency department is reduced." (Appendix Table 1). 
Other positive impacts were improved diagnostic accuracy (37%, 7/19) and 
simplified evaluation of AMI (32%, 6/19) resulting in fewer admissions, less 
additional cardiac testing, and lower costs. (Appendix Table 1).
Increased measurable hs-cTn values were the most commonly 
identified negative impact of implementation (8/18, 44%): “Increased 
awareness of myocardial necrosis without type 1 myocardial infarction 
without a clear evidence base for investigation or management in these 
patients” (Appendix Table 2). Seven participants (39%, 7/18) reported no 
negative impacts of hs-cTn implementation. Less than one third of 
participants (28%, 5/18) reported increased downstream testing or 
challenges in clinical interpretation: “Over testing/over diagnosis in patients 
without chest pain;” “Confusion among [emergency department] doctors on 
how to deal with borderline positive values.” Increased cardiology 
consultation was noted by two participants and increased hospitalizations by 
one participant.
Challenges in hs-cTn Implementation. The most frequent 
challenge which was identified by 35% (7/20) of participants was in 
education: “getting everyone on the same page” and “to make sure that 
everyone got the message and we didn’t miss anyone on the switch to the 
new assay.” Other challenges included physician buy in (20%, 4/19): “a small
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group of ER physicians… did not want numerical highly sensitive troponin 
tests that required clinical interpretation.” Participants also reported 
difficulty with over-diagnosis of AMI (15%, 3/19) and the development of new
protocols (10%, 2/19).
Leadership and Education. A multidisciplinary team led hs-cTn 
implementation at most institutions (Figure 1). Primary leadership was most 
often pathology and laboratory medicine (35%, 6/17), cardiology (29%, 
5/17), and other (29%, 5/17) [3 joint efforts, 1 unknown]. 
Education for other health care providers on hs-cTn relied on multiple 
educational tools. Used by over 60% of participants, most common 
strategies were announcements at departmental meetings, educational 
lectures, emails, and informative letters. Less than a quarter of participants 
used methods such as electronic medical record messages, online resources,
posters, or other strategies. 
DISCUSSION
Our results in a cross-sectional survey of more than 20 international 
physicians and laboratorians who use hs-cTn for the evaluation of AMI 
reveals satisfaction with the new assays and reflects important variations in 
clinical practice. To our knowledge, this is the first report that compares 
practices for hs-cTn use across multiple institutions, countries, and popular 
testing platforms. Whereas existing literature outlines the clinical algorithms 
available,13,14 our evaluation reveals the frequency of use of different clinical 
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practices and workflows with the potential to serve as a guide for other 
institutions in the process of hs-cTn implementation.
Our study group, although small, is a heterogeneous cohort 
representing diverse countries spanning North America to Australasia, a 
breadth of departments, institutions ranging from small to large, and a fairly 
even distribution of the hs-cTnI and hs-cTnT assays (Table 1). These 
attributes help broaden the applicability of our findings to other users of hs-
cTn.
One of the challenges for clinicians implementing hs-cTn is the decision
to incorporate sex-specific versus combined cut-offs. The IFCC recommends 
sex-specific cut-offs based on the distinct cut-off values for men and 
women.8 Some studies have also demonstrated an improved diagnosis of 
AMI with use of sex-specific cut-offs.15 However data on whether or not use of
sex-specific cutoffs results in improved clinical outcomes, rather than merely
diagnostic reclassification, are contradictory.9,10 Our study reveals that 
outside the US, institutions which employ hs-cTnI favor sex-specific cut-offs 
(83%) and institutions which utilize hs-cTnT favor a combined cut-off (100%).
This trend is likely a result of the hs-cTnT manufacturer, Roche, releasing 
only a combined cut-off for institutions outside the US. Facilities using hs-
cTnT are already experienced with the combined cut-off and may be 
reluctant to transition to the sex-specific cut-offs proposed by more recent 
literature.8 Additionally, the difference in use of sex-specific cut-offs by type 
of assay may be a result of reports showing that sex-specific cut-offs had a 
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negligible impact on AMI diagnosis with hs-cTnT, but a larger impact on 
diagnosis with hs-TnI.13 Institutions in the US will need to consider whether or
not to incorporate sex-specific cut-offs without consensus from international 
practices. One strategy may be to follow the trend towards a combined cut-
off since only hs-cTnT is currently available in the US. However, we caution 
against this approach since the difference between the sex-specific cut-off 
values in US populations (hs-cTnT, 8 ng/L) is larger than in populations 
outside the US (hs-cTnT, 2.5 ng/L),12 therefore making the diagnostic impact 
of sex-specific cut-offs potentially larger in the US. Additionally, Roche has 
received FDA approval for hs-cTnT sex-specific cut-offs in the US. Based on 
these key differences from the international population, we propose further 
studies to determine cut-off values from US reference populations which can 
more appropriately guide US institutions in the adoption of sex-specific cut-
offs. 
In addition to defining cut-offs, clinical protocols for the evaluation of 
AMI may also require modification. Institutions may transition to shorter 
timing intervals for serial troponin measurements since hs-cTn can more 
precisely measure lower levels of troponin and identify myocardial injury 
earlier.2,3 We found that the majority of institutions use 0 to 3 hour serial 
testing, with others applying both 0 to 1 hour and 0 to 2 hour (Table 1). 
These methods are in line with the class I recommendations from the 
European Society of Cardiology for 0 to 1 hour and 0 to 3 hour timing 
algorithms.16 A recent comprehensive review from Twerenbold, et al. 
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provides an overview of the six well-validated triage protocols using hs-cTn 
which include one 0 to 3 hour protocol, two 0 to 2 hour protocols, two 0 to 1 
hour protocols, and one single hs-cTn measurement protocol.13 Our study 
provides new information on how frequently the different timing intervals are
used among multiple institutions and countries. Currently in the US, the 
American Heart Association and American College of Cardiology recommend 
serial testing with contemporary cTn ranging from 0 to 3 hours. to 0 to 6 
hours.17 The US may need to carry out similar multicenter studies to validate 
new timing intervals and protocols in this country.
There is a paucity of data on the need for clinical risk scores or 
additional cardiac testing with hs-cTn based protocols for AMI. Prior studies 
showed similar negative predictive values and sensitivity in protocols that 
use solely troponins versus troponin combined with a clinical risk score;6,18 
however, we found that a majority (58%) of institutions use a clinical risk 
score as part of their hs-cTn protocol. Only two of the six hs-cTn protocols 
(the 0 to 3 hour European Society of Cardiology protocol and the 0 to 2 hour 
accelerated diagnostic protocol) that Twerenbold, et al describe use a clinical
risk score as part of the evaluation protocol.13 Additionally, almost three-
fourths of our surveyed institutions use additional cardiac testing, either at 
the discretion of the attending physician or as directed by the protocol, to 
rule out AMI with hs-cTn. 
All participants reported successful hs-cTn implementation and 
diagnostic utility (mean 8.6 ± 1.2 out of 10 for best implementation) with the
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major perceived benefit more rapid evaluation of AMI (74%). This is in 
accordance with a large multicenter study which showed that median time to
discharge from the emergency department decreased by 79 minutes.19 
Nearly a third of participants also reported that hs-cTn resulted in a 
simplified evaluation of AMI including fewer admissions, with the remainder 
having no comment. Nonetheless, this finding extends the data from a prior 
single center study in Sweden in which admissions for chest pain were 
reduced by 36% during the first four years after hs-cTn implementation.20 
However, post-market surveillance studies in the US are needed to better 
determine if AMI evaluation has been simplified by incorporating hs-cTn into 
routine practice. 
The most frequent response under the question of limitations was 
increased measureable hs-cTn values which included more diagnoses of type
II MI as well as measureable hs-cTn values both above and below the cut-off 
without associated acute pathology. This perceived limitation may in fact be 
an underappreciated potential benefit. High sensitivity cTn is a new 
important marker of subclinical disease with recent studies showing a strong 
association between detectable levels of hs-cTn and adverse outcomes.21,22 
These findings suggest that troponin assays are now an improved prognostic
tool.  
Few data exist on how to implement hs-cTn. This study shows that a 
multidisciplinary team usually led implementation, highlighting the 
importance of including all key stakeholders. By doing so, each department 
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or division has the opportunity to present concerns and priorities regarding 
the impact of hs-cTn on their specialty and to facilitate the education of 
colleagues. Educational efforts were multimodal including lectures, emails, 
and presentations likely to maximize the audience reached and to provide 
repetition. Other institutions can adopt this framework as an example for 
their own implementation.  
A number of limitations of our study require consideration. First, our 
study is subject to the limitations inherent in survey methods including 
sampling bias, nonresponse bias, and measurement errors. However, we 
attempted to minimize these biases by identifying >50 potential participants
from the literature, making four attempts over two months to recruit eligible 
participants, and creating well-constructed, clear survey questions. 
Additionally, a survey method was necessary in order to collect clinicians’ 
experiences with hs-cTn. Second, our sample size is small with 22 
participants. However, our 41% response rate is satisfactory, and 
participants represented diverse institutions, departments, and countries. 
Third, since we identified participants via PubMed-indexed studies, we may 
have missed clinicians who are associated with community hospitals and 
therefore our results are not reflective of community use of hs-cTn. Lastly, 
the efficacy of education programs for transitioning to hs-cTn has not been 
studied and was not evaluated in this survey.
CONCLUSIONS
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Our survey of hs-cTn implementation at international institutions 
reveals satisfaction with new assays, but points to important variations in 
clinical practice including differences in the timing and frequency of testing 
as well as use of risk scores. Education was multidisciplinary and involved 
common stakeholders including the clinical laboratory, cardiology, and 
emergency medicine. The use and values of sex-specific vs. combined cut-
offs remains controversial, including within the international community. This
is further compounded by substantial differences in sex-specific cut-off for 
the US population. To this end, facilities in the US will have to decide on the 
optimal cut-off values without consensus from the international community. 
Further studies will be needed as hs-cTn is adopted across the US to refine 
the best practices. 
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FIGURE LEGENDS
Figure 1. Implementation Leadership Team by Department
A multidisciplinary team led hs-cTn implementation at most institutions.
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